Live news related to IPSEN stock (FR0010259150): press releases, earnings publications, share price moves, analyst notes and corporate events. This page is auto-updated whenever new financial information is available.
The latest financial news on IPSEN mainly cover M&A activity, share price moves et earnings publications. The stock trades at €157,90 on Euronext Paris, up 0,06% at the last update. This page lists the articles published on IPSEN stock to track the share price, company announcements and any item likely to influence market perception.
The biopharmaceutical company stands out at the week's close, moving against the downtrend of the Parisian market. The rebound comes after several ses…
The French biopharmaceutical company is slightly in the red in early afternoon trading, moving against a well-oriented CAC 40. The stock struggles to …
On Friday, the biopharmaceutical group Ipsen announced the launch of an employee savings plan aimed at further involving its employees in the company'…
The French laboratory Ipsen strengthens the clinical profile of Iqirvo, its second-line treatment for primary biliary cholangitis (PBC). The data anno…
This Wednesday morning, the biopharmaceutical laboratory shows a significant decline, going against the grain of a well-oriented Parisian market. The …
Ipsen announced on Tuesday the results of the phase IV DIRECTION study, the first direct double-blind comparison between its products Dysport and Boto…
The biopharmaceutical company regains momentum this Tuesday mid-session, after a nearly 5% drop the previous day. The stock is priced at €158.70, in a…
The biopharmaceutical company fell sharply this Monday mid-session, among the steepest declines in the SBF 120. The stock fell to €158.10, below its 2…
Ipsen announced the resignation of Karen Witts from her role as a board member, effective after the Annual General Meeting on May 13, 2026. Having ser…
Ipsen announced on Thursday the presentation of Phase II data for corabotase, an experimental molecule classified as the first of a new therapeutic cl…
